PT2934510T - Formulações de inibidor de lfa-1 - Google Patents

Formulações de inibidor de lfa-1

Info

Publication number
PT2934510T
PT2934510T PT138657572T PT13865757T PT2934510T PT 2934510 T PT2934510 T PT 2934510T PT 138657572 T PT138657572 T PT 138657572T PT 13865757 T PT13865757 T PT 13865757T PT 2934510 T PT2934510 T PT 2934510T
Authority
PT
Portugal
Prior art keywords
lfa
inhibitor formulations
formulations
inhibitor
Prior art date
Application number
PT138657572T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2934510(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2934510T publication Critical patent/PT2934510T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT138657572T 2012-12-19 2013-12-18 Formulações de inibidor de lfa-1 PT2934510T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US201361758147P 2013-01-29 2013-01-29

Publications (1)

Publication Number Publication Date
PT2934510T true PT2934510T (pt) 2021-01-13

Family

ID=50979140

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138657572T PT2934510T (pt) 2012-12-19 2013-12-18 Formulações de inibidor de lfa-1

Country Status (20)

Country Link
US (2) US11058677B2 (enExample)
EP (2) EP3827823A1 (enExample)
JP (1) JP6373867B2 (enExample)
KR (1) KR101891144B1 (enExample)
CN (1) CN104955453B (enExample)
AU (1) AU2013361579B2 (enExample)
BR (1) BR112015014367B1 (enExample)
CA (1) CA2894170C (enExample)
DK (1) DK2934510T3 (enExample)
EA (2) EA201791321A1 (enExample)
ES (1) ES2846724T3 (enExample)
HU (1) HUE052299T2 (enExample)
IL (1) IL239490B (enExample)
MX (2) MX391620B (enExample)
NZ (1) NZ708821A (enExample)
PL (1) PL2934510T3 (enExample)
PT (1) PT2934510T (enExample)
SI (1) SI2934510T1 (enExample)
WO (1) WO2014100135A1 (enExample)
ZA (2) ZA201504404B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
WO2020212755A1 (en) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
CN116635032A (zh) * 2020-10-21 2023-08-22 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
KR20260109029A (ko) 2023-11-02 2026-07-09 노바리크 게엠베하 리피테그라스트를 포함하는 세미플루오르화 알칸 조성물
CN122349415A (zh) * 2023-11-17 2026-07-07 博士伦爱尔兰有限公司 用于治疗眼部病症的半氟化烷烃小分子lfa-1拮抗剂复方组合物
CN117771174B (zh) * 2023-12-29 2025-07-29 鲁南贝特制药有限公司 一种立他司特滴眼液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
EP1901708B1 (en) * 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2010033800A2 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
US20110212142A1 (en) * 2008-11-17 2011-09-01 Laila Pharmaceuticals Pvt.Ltd. Curcuminoids and its metabolites for the application in ocular diseases
EA025414B1 (ru) * 2009-06-10 2016-12-30 Общество С Ограниченной Ответственностью "Митотех" Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
KR20120085330A (ko) * 2009-11-23 2012-07-31 알러간, 인코포레이티드 결정형 ｉｉ의 ７?〔３,５?다이하이드록시?２?(３?하이드록시?５?페닐?펜트?１?에닐)?사이클로펜틸〕?ｎ?에틸?헵트?５?엔아마이드(비마토프로스트), 그의 제조방법 및 이용방법
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
EP2675455A4 (en) * 2011-02-18 2014-07-16 M S Appasamy Associates OPHTHALMIC COMPOSITION FOR DILATING PUPILS
BR112013034055A2 (pt) * 2011-06-29 2017-02-07 Allergan Inc alcaftadina para uso no tratamento de urticária
EP4420725A3 (en) * 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
CA2894170C (en) 2021-08-10
EP2934510A4 (en) 2016-08-17
HK1214963A1 (en) 2016-08-12
MX368876B (es) 2019-10-21
ES2846724T3 (es) 2021-07-29
EP3827823A1 (en) 2021-06-02
IL239490B (en) 2018-12-31
JP2016503058A (ja) 2016-02-01
US20220000859A1 (en) 2022-01-06
EA028008B1 (ru) 2017-09-29
CN104955453B (zh) 2018-09-18
CN104955453A (zh) 2015-09-30
BR112015014367B1 (pt) 2022-11-22
IL239490A0 (en) 2015-08-31
ZA201608069B (en) 2017-11-29
KR101891144B1 (ko) 2018-08-23
WO2014100135A1 (en) 2014-06-26
HK1214536A1 (zh) 2016-07-29
AU2013361579A1 (en) 2015-06-18
EP2934510B1 (en) 2020-10-28
PL2934510T3 (pl) 2021-07-05
EA201791321A1 (ru) 2018-04-30
US20150320737A1 (en) 2015-11-12
CA2894170A1 (en) 2014-06-26
SI2934510T1 (sl) 2021-02-26
JP6373867B2 (ja) 2018-08-15
BR112015014367A2 (pt) 2017-07-11
US11058677B2 (en) 2021-07-13
KR20150100763A (ko) 2015-09-02
DK2934510T3 (da) 2021-01-25
ZA201504404B (en) 2020-01-29
EA201591180A1 (ru) 2015-12-30
MX391620B (es) 2025-03-19
NZ708821A (en) 2020-03-27
MX2019012375A (es) 2020-01-20
MX2015007540A (es) 2016-04-13
AU2013361579B2 (en) 2018-05-24
HUE052299T2 (hu) 2021-04-28
EP2934510A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
SI2892889T1 (sl) Inhibitorske spojine
HUE044300T2 (hu) 3-amino-cikloalkil-vegyületek, mint ROR-GAMMA-T inhibitorok és alkalmazásuk
GB2524921B (en) Pusher
ZA201608069B (en) Lfa-1 inhibitor formulations
HUE051744T2 (hu) Kitozánból származtatott készítmények
GB2511197B (en) Compositions
IL235919A0 (en) inhibitors of fbxo3
GB201209244D0 (en) Compositions
GB201210800D0 (en) Compositions
GB201201287D0 (en) Compositions
GB201211019D0 (en) Inhibitor compounds
GB201220068D0 (en) Compositions
GB201318407D0 (en) Compositions
GB201219973D0 (en) Compositions
GB201219962D0 (en) Compositions
GB201219980D0 (en) Compositions
GB201206178D0 (en) Formulations
GB201216524D0 (en) Project P
GB201200323D0 (en) Easihang 45?/90?
GB201220595D0 (en) Keysafe application
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201213825D0 (en) Damper-device for bouncing-device
GB201211247D0 (en) Improved formulation
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions